Pfizer plans fight to hold share against generic cholesterol drugs

10/17/2005 | NYTimes.com

Insurers and government agencies look forward to billions of dollars in savings when they can move patients from Pfizer's cholesterol drug Lipitor to less expensive generics such as Merck's Zocor and newer generics expected to hit the market. Merck's patent on Zocor expires in June; Pfizer plans to fight the migration to generic versions of Zocor by using its marketing muscle and clinical data showing Lipitor is more effective than the generics.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations